Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784)
11/2000
11/23/2000CA2372304A1 Previns as specific inhibitors and therapeutic agents for botulinum toxin b and tetanus neurotoxins
11/23/2000CA2372200A1 Self-assembling biomolecular structures
11/23/2000CA2372128A1 Novel indications of mannan-binding lectin (mbl) in the treatment of immunocompromised individuals
11/23/2000CA2372119A1 Neuroprotective properties of gdf-15, a novel member of the tgf-.beta. superfamily
11/23/2000CA2372068A1 Sulphostin analogue and process for producing sulphostin and its analogue
11/23/2000CA2372051A1 Imidazo-containing heterocyclic compounds, their compositions and uses
11/23/2000CA2371245A1 Crystal structure of ribosomal protein l11/gtpase activating region rrna and uses thereof
11/23/2000CA2371212A1 Differential gene expression in specific regions of the brain in neurodegenerative diseases
11/23/2000CA2369369A1 Buforin 1 as a specific inhibitor and therapeutic agent for botulinum toxin b and tetanus neurotoxins
11/23/2000CA2368640A1 A composition containing carvacrol and thymol for use as a bactericide
11/23/2000CA2368593A1 Anti-inflammatory therapy for inflammatory mediated infection
11/22/2000EP1054007A2 Method for the preparation of (+/-)-calanolide A
11/22/2000EP1053989A2 Hydroxydiphenyl ether compounds
11/22/2000EP1053747A2 Composition for treating topical periodontal infection
11/22/2000EP1053744A2 Substituted phenols as fragrance, flavor and antimicrobial compounds
11/22/2000EP1053343A2 Targeting of genetic vaccine vectors
11/22/2000EP1053332A1 Protein
11/22/2000EP1053329A1 RECOMBINANT LIPIDATED PsaA PROTEIN, METHODS OF PREPARATION AND USE
11/22/2000EP1053312A2 Optimization of immunomodulatory properties of genetic vaccines
11/22/2000EP1053308A1 Dendritic enriched secreted lymphocyte activation molecule
11/22/2000EP1053249A2 Peptide inhibitors of the serine protease activity associated to the ns3 protein of hcv, relevant uses and process of production
11/22/2000EP1053247A1 Antifungal cyclohexapeptides
11/22/2000EP1053233A1 Hydroxamic and carboxylic acid derivatives
11/22/2000EP1053230A1 Triazine antiviral compounds
11/22/2000EP1053029A1 Sterile complex of therapeutic peptide bond to a polysaccharide
11/22/2000EP1053017A2 Vaccines comprising interleukin-12 and herpes simplex viral antigen
11/22/2000EP1053016A2 Vaccines comprising interleukin-12 and respiratory syncytial viral antigens
11/22/2000EP1053015A2 Pneumococcal and meningococcal vaccines formulated with interleukin-12
11/22/2000EP1053014A1 BIOLOGICALLY ACTIVE HEMAGGLUTININ FROM TYPE A $i(CLOSTRIDIUM BOTULINUM) AND METHODS OF USE
11/22/2000EP1053012A1 Pharmaceutical compositions comprising peg-asparaginase for the treatment of hiv infections
11/22/2000EP1052992A1 Cyclic amine modulators of chemokine receptor activity
11/22/2000EP1052984A1 Antibacterial agents
11/22/2000EP1052963A1 Compositions and methods of treating keratin-related disorders and conditions
11/22/2000EP0722327B1 Improvements relating to antibacterial compositions
11/22/2000EP0586535B1 Methods and compositions based on inhibition of cell invasion and fibrosis by dextran sulfate
11/22/2000CN1274387A HCVE mimotopes of hypervariable region 1 and uses
11/22/2000CN1274354A Robustaflavone, intermediates and analogues and method for prepn. method
11/22/2000CN1273832A Compound Yexiazhu medicine and preparing process thereof
11/22/2000CN1273827A Disinfecting liquid for treating tinea and pile
11/22/2000CN1273826A Method for preventing by-effect of clamycin as injection
11/22/2000CN1273824A Exterior-applied medicine containing phosphonomycin calcium and its application
11/22/2000CN1273819A Release-controlled Chinese-medicinal picking for reducing baby fever caused by cold
11/22/2000CN1058723C D4T polymorphic form I process
11/22/2000CN1058621C External-use ointment for treating bone tuberculosis
11/22/2000CN1058609C Medical application of compound morusin
11/21/2000US6150588 DNA encoding antimicrobial proteins from impatiens
11/21/2000US6150557 Compounds
11/21/2000US6150556 Bis-amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors
11/21/2000US6150530 Amidation of amine with acid
11/21/2000US6150502 Polypeptides expressed in skin cells
11/21/2000US6150414 Inhibiting a virus causing infection (such as hiv) by administering the compound 1,3,4,6-tetrahydroxy-7,16-dioxo-7,16-dihydro-dibenzo(a,o)perylene
11/21/2000US6150385 Viricide with activity against cytomegalo virus (cmv), herpes virus including varicella zoster virus, the epstein-barr virus, the herpes simplex virus, and the human herpes virus type 8 (hhv-8)
11/21/2000US6150351 Cephem compounds and pharmaceutical use thereof
11/21/2000US6150350 Carbapenem antibiotic and beta-lactamase inhibitor, useful for the treatment and prophylaxis of infectious diseases
11/21/2000US6150340 RNA-dependent amidotransferase from Staphylococcus aureus
11/21/2000US6150339 Anti-viral guanosine-rich oligonucleotides
11/21/2000US6150325 Bicyclic tachykinins antagonists, preparation thereof and their use in pharmaceutical compositions
11/21/2000US6150134 Recombinant microorganism polypeptide; for the diagnosis, treatment and prevention of preferential microorganismal infections; for the purification of recombinant polypeptides
11/21/2000US6150132 Vector coding polypeptides for the diagnosis and treatment of allergies and atherosclerosis; for the prevention of graft ejection and injuries to stem cell caused by anticarcinogenic agents
11/21/2000US6150109 Lipophilic quenching of viral inactivating agents
11/21/2000US6150087 Non-hepatitis a or b virus polypeptide which is capable of illiciting immune response with hepatitus virus antibodies, for the treatment of and prevention of viral infections
11/21/2000US6149947 Compositions of oak bark extract related synthetic compositions and method of using same
11/21/2000US6149920 Vaccine for immunization, prophylaxis or treatment of a vertebrate at risk of or suffering from brucellosis, wherein said vaccine comprises an attenuated or avirulent strain of an otherwise pathogenic bacteria of the genus brucella
11/21/2000US6149919 Immunogenic detoxified mutants of cholera toxin and of the toxin LT, their preparation and their use for the preparation of vaccines
11/21/2000US6149908 Use of lactoperoxidase, a peroxide donor and thiocyanate for the manufacture of a medicament for treating Helicobacter pylori infection
11/21/2000CA2040854C Chiral 2-(phosphonomethoxy)propyl guanines as antiviral agents
11/21/2000CA2038578C Delivery of agents
11/21/2000CA2019812C Novel 5,11-dihydro-6h-dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-ones and their use in the prevention or treatment of aids
11/21/2000CA2010085C Pentamidine solutions
11/16/2000WO2000068413A1 Halo- or hydroxy-substituted nocathiacin antibiotics
11/16/2000WO2000068387A2 Nucleic acids and proteins with interferon-beta activity
11/16/2000WO2000068385A2 Novel nucleic acids and proteins with growth hormone activity
11/16/2000WO2000068380A2 Extracellular matrix and adhesion-associated proteins
11/16/2000WO2000068263A2 Stereoselective antifibrillogenic peptides and peptidomimetics thereof
11/16/2000WO2000068261A2 Attenuated microorganisms for the treatment of infection
11/16/2000WO2000068258A2 Compounds exhibiting an antibiotic activity
11/16/2000WO2000068256A1 Cephaibols, novel antiparasitics from acremonium tubakii, method for the production and the utilization thereof
11/16/2000WO2000068243A1 Methods using mechanisms of action of aroa
11/16/2000WO2000068241A1 Processes for the synthesis of oligomers using phusphoramidite compositions
11/16/2000WO2000068235A1 Thiazepine inhibitors of hiv-1 integrase
11/16/2000WO2000068224A1 Substituted benzolactam compounds
11/16/2000WO2000068206A1 Heterocyclically substituted benzimidazoles, the production and application thereof
11/16/2000WO2000068203A1 Cyclic compounds and uses thereof
11/16/2000WO2000068198A2 Heterosubstituted pyridine derivatives as pde 4 inhibitors
11/16/2000WO2000068186A1 Bis-sulfonamide with anti-hcmv effect
11/16/2000WO2000068185A1 A structure-based approach to design inhibitors of protein-processivity factor interactions
11/16/2000WO2000068140A1 Signal transduction response regulator family of staphylococcus
11/16/2000WO2000067917A1 Permeabilizing biofilms
11/16/2000WO2000067801A2 Prodrugs of chemotherapeutic agents with oxaalkanoic acids
11/16/2000WO2000067796A1 Treatment of autoimmune diseases with antagonists which bind to b cell surface markers
11/16/2000WO2000067793A1 Death domain containing receptor 4
11/16/2000WO2000067791A1 Ccr4 antagonists in sepsis
11/16/2000WO2000067790A1 Method for treating tnf-receptor type-2-induced diseases
11/16/2000WO2000067787A2 Hiv immunogenic compositions and methods
11/16/2000WO2000067786A1 PRODUCTION OF NOVEL NEWCASTLE DISEASE VIRUS STRAINS FROM cDNAS AND IMPROVED LIVE ATTENUATED NEWCASTLE DISEASE VACCINES
11/16/2000WO2000067785A2 Staphyloccocus aureus antigen-containing whole cell vaccine
11/16/2000WO2000067783A1 509hk
11/16/2000WO2000067780A1 Methods of modulating fabh activity
11/16/2000WO2000067776A1 Pharmacokinetic and pharmacodynamic modeling of erythropoietin administration
11/16/2000WO2000067769A1 Enhanced survival of cancer patients treated with erythropoietin and antitumor agents
1 ... 1427 1428 1429 1430 1431 1432 1433 1434 1435 1436 1437 1438 1439 1440 1441 1442 1443 1444 1445 1446 1447 ... 1798